Prevention and Treatment of Recurrence and Metastasis of Hepatocellular Carcinoma after Operation with Ganyanshu Decoctions
- Conditions
- Hepatocellular Carcinoma
- Registration Number
- ITMCTR2000003577
- Lead Sponsor
- onghua Hospital, Shanghai University of Traditional Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
(1) With reference to the 2018 edition of the systems of primary liver cancer diagnosis and treatment guidelines and the 2018 edition of the diagnosis and treatment of hepatocellular carcinoma (HCC) merger portal venous tumor emboli multidisciplinary China expert consensus, the eighth edition of the AJCC TNM staging system standards and PVTT program classification, selection of stage Ia, Ib merge each type of portal venous tumor emboli and II - stage IIIb (and/or merge each type of portal venous tumor emboli) of postoperative patients with liver cancer;
(2) Estimated survival >=3 months;
(3) Physical condition (ECOG) score <=2;
(4) Aged 18 to 80 years old;
(5) Patients voluntarily participate in the study of this project and sign informed consent.
(1) Patients with a history of other malignant tumors;
(2) having a serious or uncontrolled medical condition or an infected person;
(3) Participating in other clinical studies or participating in other clinical studies within 1 month.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method DFS;
- Secondary Outcome Measures
Name Time Method AFP;OS;